Contact
searchSearch
HMP Global

Hepatology Excellence Forum

Hepatology
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Zobair Younossi
Expert Insights
How I Treat MASLD/MASH
05/11/2026
Zobair Younossi, MD
Dr Younossi reviews his approach to managing MASLD and MASH, from screening to treatment to monitoring, and how working with a multidisciplinary team provides for better outcomes.
Dr Younossi reviews his approach to managing MASLD and MASH, from screening to treatment to monitoring, and how working with a multidisciplinary team provides for better outcomes.
Dr Younossi reviews his approach...
05/11/2026
Gastroenterology
Zobair Younossi
How I Treat MASLD/MASH
The advent of noninvasive testing methods for liver steatosis and the approval of 2 drugs to treat MASLD and MASH has positioned clinicians in primary care and internal medicine to screen...
Expert Roundtable
Advances in the Pipeline for MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the...
04/17/2026
Gastroenterology
Expert Roundtable
Monitoring Patients With MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on...
04/17/2026
Gastroenterology
Expert Roundtable
GLP-1s, Resmetirom, Dual Therapy and More: Roundtable Continued
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on...
03/30/2026
Gastroenterology
Expert Roundtable
Approved Medications for MASLD/MASH
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable...
03/30/2026
Gastroenterology
Treatment Guidance
Managing MASLD and MASH: Expert Roundtable Part 4
01/27/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
As hepatologists Nezam Afdhal, Meena Bansal, and Zobair Younossi continue their expert roundtable, the topic turns to the management of MASLD and MASH, including the best use of two new types of drugs--resmetirom and the GLP-1 agonists.
As hepatologists Nezam Afdhal, Meena Bansal, and Zobair Younossi continue their expert roundtable, the topic turns to the management of MASLD and MASH, including the best use of two new types of drugs--resmetirom and the GLP-1 agonists.
As hepatologists Nezam Afdhal,...
01/27/2026
Gastroenterology
Expert Insights
When to Refer Patients to Hepatology for MASLD/MASH
01/27/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
The expert panel on MASLD and MASH continues its discussion with guidance on when a patients with suspected steatotic liver disease should be referred to a hepatology specialist.
The expert panel on MASLD and MASH continues its discussion with guidance on when a patients with suspected steatotic liver disease should be referred to a hepatology specialist.
The expert panel on MASLD and...
01/27/2026
Gastroenterology
Expert Insights
Screening for MASLD and MASH: Expert Roundtable Part 2
01/19/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 2 of this expert roundtable Drs Afdhal, Bansal, and Younossi discuss how to determine which patients need to be screened for MASLD/MASH, how to conduct screening, and which modalities are best.
In Part 2 of this expert roundtable Drs Afdhal, Bansal, and Younossi discuss how to determine which patients need to be screened for MASLD/MASH, how to conduct screening, and which modalities are best.
In Part 2 of this expert...
01/19/2026
Gastroenterology
Expert Insights
Expert Roundtable on MASLD/MASH: Part 1
01/15/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart...
01/15/2026
Gastroenterology

News

Research Review
High Rehospitalization and Mortality Rates Persist After ICI-Associated Colitis
05/06/2026
Jessica Garlewicz
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained...
05/06/2026
Gastroenterology
Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
News
Lifetime Alcohol Intake Linked to Colorectal Cancer Risk
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use